Comparison of Immunic Inc. (IMUX) and CRISPR Therapeutics AG (NASDAQ:CRSP)

Immunic Inc. (NASDAQ:IMUX) and CRISPR Therapeutics AG (NASDAQ:CRSP) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immunic Inc. 12 0.00 N/A -34.26 0.00
CRISPR Therapeutics AG 40 1928.88 N/A -3.74 0.00

In table 1 we can see Immunic Inc. and CRISPR Therapeutics AG’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Immunic Inc. 0.00% -235.3% -182.3%
CRISPR Therapeutics AG 0.00% -50.9% -39.8%

Liquidity

The current Quick Ratio of Immunic Inc. is 7 while its Current Ratio is 7. Meanwhile, CRISPR Therapeutics AG has a Current Ratio of 15.8 while its Quick Ratio is 15.8. CRISPR Therapeutics AG is better positioned to pay off its short-term and long-term debts than Immunic Inc.

Analyst Ratings

The Recommendations and Ratings for Immunic Inc. and CRISPR Therapeutics AG are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Immunic Inc. 0 0 1 3.00
CRISPR Therapeutics AG 0 0 3 3.00

Immunic Inc.’s upside potential is 210.08% at a $40 average price target. Competitively the average price target of CRISPR Therapeutics AG is $62, which is potential 32.71% upside. The data provided earlier shows that Immunic Inc. appears more favorable than CRISPR Therapeutics AG, based on analyst opinion.

Insider and Institutional Ownership

The shares of both Immunic Inc. and CRISPR Therapeutics AG are owned by institutional investors at 1.6% and 50% respectively. Insiders held 0.3% of Immunic Inc. shares. On the other hand, insiders held about 2% of CRISPR Therapeutics AG’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Immunic Inc. 1.94% 21.1% 2.94% 71.52% -95.65% 83.31%
CRISPR Therapeutics AG 3.15% 6.25% 30.58% 57.23% 7.51% 77.42%

For the past year Immunic Inc.’s stock price has bigger growth than CRISPR Therapeutics AG.

Summary

CRISPR Therapeutics AG beats on 6 of the 8 factors Immunic Inc.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.